Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$580+ Million Settlement – Cathode Ray Tube (CRT) Antitrust Litigation
In re Cathode Ray Tube (CRT) Antitrust Litigation, MDL 1917 (U.S. District Court for the Northern District of California)Milberg represented indirect purchaser plaintiffs in this class action alleging an international conspiracy among defendants to keep prices for cathode ray tube (CRT) displays artificially high. Milberg had a significant discovery role in the prosecution of this class action with settlements exceeding $580 million. -
See More$775 Million Settlement – Washington Public Power Supply System Securities Litigation
In re Washington Public Power Supply System Securities Litigation, MDL 551 (D. Ariz.)In this massive securities fraud litigation, Milberg served as Co-Lead Counsel for a class that obtained, after several months of trial, settlements totaling $775 million, the largest securities fraud settlement at that time. -
See More$1+ Billion Settlement – Merck & Co., Inc. Securities Litigation
In re Merck & Co., Inc. Securities Litigation, Nos. 05-1151 and 05-2367 (D.N.J.)Milberg served as Co-Lead Counsel in this federal securities fraud class action, and after more than 12 years of hard-fought litigation, ultimately obtained a combined settlement totaling $1.062 billion, the largest securities class action settlement ever against a pharmaceutical company. The Court described the settlement as “a settlement which is fair and just and which, in fact, is the best settlement which possibly could have been achieved in this case.” -
See More$62 Million Settlement – Comverse Technology, Inc. Derivative Litigation
In re Comverse Technology, Inc. Derivative Litigation, No. 601272/2006 (N.Y. Sup. Ct. N.Y. Cnty.)As Co-Lead Counsel, Milberg negotiated a $62 settlement which was approved by the court in 2010. The settlement also resulted in significant corporate governance reforms, including the replacement of various directors and officers; the amendment of the company’s bylaws to permit certain shareholders to propose in the company’s proxy materials nominees for election as directors; and the requirement that all equity grants be approved by both the compensation committee and a majority of the non-employee directors. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.
